Open Access Open Access  Restricted Access Subscription or Fee Access

The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain

Jasmina I. Ivanova, MA, Howard G. Birnbaum, PhD, Yana Yushkina, BA, Rachael A. Sorg, MPH, John Reed, MD, Sanjay Merchant, MBA, PhD

Abstract


Objectives: To estimate the prevalence of opioid-related side effects among patients with chronic noncancer pain (CNCP) who initiated opioids and compare healthcare costs of patients with and without side effects using patient survey, medical charts, and claims data.

Patients, participants: Patients initiating opioids, who were aged 18 years, had 1 pain diagnosis, and did not have cancer, were identified through claims data and medical records from a Central Massachusetts medical group practice and mailed surveys between October 2010 and July 2012.

Main outcomes measures: Prevalence of opioid-related side effects was estimated from patient surveys, charts, and claims data within 90 days after opioid initiation (study period). Study period healthcare costs were compared between patients with and without side effects (self-reported problematic side effects or side effects recorded in medical charts or claims).

Results: Among patients with CNCP who initiated opioids and completed the survey (N = 167), the average age was 53 years, and 62.9 percent were women. Based on the survey, charts, and claims, 91.6 percent, 15.0 percent, and 19.2 percent of patients, respectively, had 1 opioid-related side effect. Overall, 59.3 percent of patients reported having 1 problematic side effect or side effect recorded in charts or claims. In the analysis that controlled for baseline characteristics and resource use, patients with versus without side effects had higher mean study period healthcare costs ($3,347 vs $2,521, p = 0.049).

Conclusions: Prevalence of opioid-related side effects among patients with CNCP who initiated opioids was substantially higher based on patient survey than from charts or claims. Opioid-related side effects were associated with significantly higher healthcare costs.


Keywords


chronic noncancer pain, prescription opioids, opioid-related side effects, prevalence, resource use, costs

Full Text:

PDF

References


Noble M, Treadwell JR, Tregear SJ, et al.: Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010; (1): CD006605.

Institute of Medicine of the National Academies: Relieving pain in America: A blueprint for transforming prevention, care, education, and research. Available at www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx. Accessed December 6, 2012.

Johannes CB, Le TK, Zhou X, et al.: The prevalence of chronic pain in United States adults: Results of an internet-based survey. J Pain. 2010; 11(11): 1230-1239.

Chapman RC, Lipschitz DL, Angst MS, et al.: Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base. J Pain. 2010; 11(9): 807-829.

Sullivan MD, Edlund MJ, Fan MY, et al.: Trends in use of opioids for non-cancer pain conditions 2000-2005 in Commercial and Medicaid insurance plans: The TROUP study. Pain. 2008; 138: 440-449.

Trescot AM, Helm S, Hansen H, et al.: Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians’ (ASIPP) Guidelines. Pain Physician. 2008; 11(2 Suppl): S5-S62.

Kalso E, Edwards JE, Moore RA, et al.: Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 2004; 112(3): 372-380.

Moore RA, McQuay HJ: Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005; 7: R1046-R1051.

Tuteja AK, Biskupiak J, Stoddard GJ, et al.: Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010; 22: 424-e96.

Chan BKB, Tam LK, Wat CY, et al.: Opioids in chronic noncancer pain. Expert Opin Pharacother. 2011; 12(5): 705-720.

Sullivan MD, Von Korff M, Banta-Green C, et al.: Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain. 2010; 149: 345-353.

Atluri S, Akbik H, Sudarshan G: Prevention of opioid abuse in chronic non-cancer pain: An algorithmic, evidence based approach. Pain Physician. 2012; 15: ES177-ES189.

Annemans L: Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. Clin Drug Investig. 2011; 31(2): 73-86.

Manchikanti L, Helm S, Fellows B, et al.: Opioid epidemic in the United States Pain Physician. 2012; 15: ES9-ES38.

Candiotti KA, Gitlin MC: Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: Tapentadol, a step toward a solution? Curr Med Res Opin. 2010; 26: 1677-1684.

Summers KH, Puenpatom RA, Rajan N, et al.: Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ. 2011; 14(4): 390-396.

Rauck RL: What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract. 2009; 9(6): 468-479.

Nicholson B: Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract. 2008; 9(1): 71-81.

Jonsson T, Christrup LL, H?jsted J, et al.: Symptoms and side effects in chronic non-cancer pain: Patient report vs. systematic assessment. Acta Anaesthesiol Scand. 2011; 55: 69-74.

Neighbors DM, Bell TJ, Wilson J, et al.: Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001; 21(2): 129-143.

Anastassopoulos KP, Chow W, Tapia CI, et al.: Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. J Manag Care Pharm. 2012; 18(8): 615-626.

Iyer S, Davis KL, Candrilli S: Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010; 19(3): 44-51.

Kwong WJ, Diels J, Kavanagh S: Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010; 44(4): 630-640.

Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40(5): 373-383.

Romano PS, Roos LL, Jollis J: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol. 1993; 46(10): 1075-1079.

Boswell K, Kwong WJ, Kavanagh S: Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: A systematic literature review. J Opioid Manag. 2010; 6(4): 269-289.

Gregorian RS Jr, Gasik A, Kwong WJ, et al.: Importance of side effects in opioid treatment: A trade-off analysis with patients and physicians. J Pain. 2010; 11(11): 1095-1108.

Gudin J: Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012; 44(6 Suppl): S4-14.

Braden JB, Russo J, Fan MY, et al.: Emergency department visits among recipients of chronic opioid therapy. Arch Int Med. 2010; 170(16): 1425-1432.

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality: The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Available at http://www.samhsa.gov/data/2k12/DAWN096/SR096EDHighlights2010.pdf. Accessed April 5, 2013.




DOI: https://doi.org/10.5055/jom.2013.0165

Refbacks

  • There are currently no refbacks.